The global human microbiome market is projected to reach $1.9 billion by 2028, at a CAGR of 18.6% during 2023-2028. The growth of human microbiome market is driven by increasing focus on human microbiome therapies and growing technological advancements in metagenomics and next-generation sequencing.
Some of the Key Questions answered in this exclusive report are:
Q.1 What are some of the most promising, high-growth opportunities for the human microbiome market by product (prebiotics, probiotics, food, medical food, and drugs), disease type (infectious, metabolic/endocrine, cancer, blood, and neurological), research technology (proteomics, metabolomics, and genomics), application (therapeutics and diagnostics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 What are the business risks and threats to the human microbiome market?
Q.4 What are some changing demands of customers in the human microbiome market?
Q.5 What are the new developments in the human microbiome market? Which companies are leading these developments?
Q.6 What strategic initiatives are being implemented by key players for business growth?
Q.7 What are some of the competitive products and processes in this human microbiome area and how big of a threat do they pose for loss of market share via product substitution?
Q.8 What M&A activity has occurred in the last 5 years in this human microbiome market?
Emerging trends, which have a direct impact on the dynamics of the industry, include usage of bacterial microbiome for cancer treatment and introduction of next-generation probiotic microbiota-derived molecules for treatment of obesity.
Market Segmentation:
Based on product, the human microbiome market is segmented into prebiotics, probiotics, food, medical food, and drugs. The probiotics segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to increasing health concerns; growing awareness of the relationship between nutrition, diet, and health; and increasing penetration of the probiotic market in dairy and other foods.
North America will remain the largest region over the forecast period due to increasing incidence of lifestyle-related diseases, rising awareness of preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products. APAC is expected to witness the highest growth over the forecast period due rising chronic diseases caused by changes in lifestyle and growing interest in human microbiome treatment approaches.
Key Players in the human microbiome market are Enterome, Seres Therapeutics, 4D Pharma, DuPont, Vedanta Biosciences, Osel, Merck & Co., Second Genome, and Metabiomics Corporation.
Request Sample Pages by clicking on https://www.lucintel.com/human-microbiome-market.aspx
The report helps stakeholders understand the pulse of the market and provides them with information on key drivers, restraints, challenges, and opportunities for market growth. It would also help to understand the competitors better and gain more insights to improve their position in the business.
To read more about this market please click on https://www.lucintel.com/human-microbiome-market.aspx
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
Roy AlmaguerLucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. 972.636.5056
Media Contact
Company Name: Lucintel
Contact Person: Roy Almaguer
Email: Send Email
Phone: 972.636.5056
Address:8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/